Business
PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract highlights 3/10 (30%) partial responses in patients
About this update from Pmv Pharmaceuticals, Inc.
[{"type":"text","content":"Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract highlights 3/10 (30%) partial responses in patients treated in higher dose cohorts and activity observed in multiple tumor typesUpdated data from ongoing Phase 1/2 PYNNACLE trial to be presented during oral presentation on June 7Company to host an investor event on June 7 to review data presented CRANBURY, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the online publication of the abstract for its lead program, PC14586, accepted as an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting being held June 3-7, 2022 in Chicago, Illinois. The published abstract describes preliminary outcomes from 29 patients, including 21 efficacy evaluable, from the ongoing Phase 1/2 PYNNACLE trial of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation. These initial data from our Phase 1/2 tumor agnostic study enrolled patients across multiple tumor types over a broad range of doses. The preliminary clinical pharmacokinetics data showed dose proportional increases in Cmax and AUC. In addition, the safety profile was encouraging as PC14586 was well-tolerated. The oral presentation at ASCO containing updated data from the trial will be presented by Ecaterina Ileana Dumbrava, M.D., of the University of Texas MD Anderson Cancer Center. PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors. “Patients whose tumors carry a p53 mutation are known to have a poor prognosis. The patients who were enrolled in our study had very limited or no other standard treatment options available to them. Early efficacy and safety data from this Phase 1/2 trial provide the potential of a p53 therapy,” said David Mack, Ph.D., President and CEO, PMV Pharma. “We look forward to Dr. Dumbrava’s presentation of these data at ASCO and continuing to progress the PC14586 development program.” Details of the oral presentation are as follows: Abstract Title: First-in-human study of PC14586, a small molecule structural corrector of Y2...